A phase II, multicenter, single-arm study of parsaclisib, a PI3K delta inhibitor, in relapsed or refractory follicular lymphoma in China: Updated data from the study.

JOURNAL OF CLINICAL ONCOLOGY

LIPPINCOTT WILLIAMS & WILKINS

1. Innovent Biologics Inc.